Natixis’s Guardian Pharmacy Services GRDN Stock Holding History

Natixis’s Portfolio GRDN Stock Details GRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-170	Closed	-$5.12K	–	1361
2025 Q4	$5.12K	Buy	+170	New	+$4.81K	﹤0.01%	1067

Other funds holding GRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VCM

Valiant Capital Management San Francisco, California $1.74B AUM 64.05% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Natixis's GRDN Position: Q1 2026 in Review

Natixis sold out of Guardian Pharmacy Services (GRDN) in Q1 2026, closing a stake of 170 shares — an estimated $5.12K sold.

Natixis first reported a position in GRDN in Q4 2025 and held it in 1 quarter. The position peaked at $5.12K in Q4 2025. 171 funds tracked by Wall St. Rank hold GRDN as of Q1 2026.

Natixis reported no remaining Guardian Pharmacy Services position as of Q1 2026 after selling out during the quarter.
Natixis sold 170 Guardian Pharmacy Services shares in Q1 2026, an estimated $5.12K.
Natixis first reported a position in Guardian Pharmacy Services in Q4 2025 and held it in 1 quarter.
Natixis's Guardian Pharmacy Services position peaked at $5.12K in Q4 2025.
171 funds tracked by Wall St. Rank held Guardian Pharmacy Services as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.